Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society.

The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.

[1]  T. Hwang,et al.  DNA degradation in liquid‐based cytology and its comparison with conventional smear , 2016, Diagnostic cytopathology.

[2]  I. Wistuba,et al.  Optimizing the DNA yield for molecular analysis from cytologic preparations , 2016, Cancer cytopathology.

[3]  R. Broaddus,et al.  Factors affecting the success of next‐generation sequencing in cytology specimens , 2015, Cancer cytopathology.

[4]  K. Azuma,et al.  Epidermal growth factor receptor mutation status in cell‐free DNA supernatant of bronchial washings and brushings , 2015, Cancer cytopathology.

[5]  A. Ambaye,et al.  Increased utilization, verification, and clinical implications of immunocytochemistry: Experience in a northern New England hospital , 2015, Diagnostic cytopathology.

[6]  V. Ganju,et al.  The Evolution of Therapies in Non-Small Cell Lung Cancer , 2015, Cancers.

[7]  R. Goswami,et al.  Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies , 2015, Cancers.

[8]  G. da Cunha Santos,et al.  Preanalytic parameters in epidermal growth factor receptor mutation testing for non–small cell lung carcinoma: A review of cytologic series , 2015, Cancer cytopathology.

[9]  C. Schumann,et al.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. , 2015, The Lancet. Oncology.

[10]  M. Roh.  The Utilization of Cytologic Fine-Needle Aspirates of Lung Cancer for Molecular Diagnostic Testing , 2015, Journal of pathology and translational medicine.

[11]  Yi Liu,et al.  Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. , 2015, The Journal of molecular diagnostics : JMD.

[12]  C. Dumur,et al.  Next‐generation sequencing and the cytopathologist , 2015, Cancer cytopathology.

[13]  Shingo Matsumoto,et al.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.

[14]  Michael P. Gailey,et al.  Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin‐fixed, paraffin‐embedded tissue , 2015, Cancer cytopathology.

[15]  V. Iyer,et al.  Cell blocks in cytopathology: a review of preparative methods, utility in diagnosis and role in ancillary studies , 2014, Cytopathology : official journal of the British Society for Clinical Cytology.

[16]  P. Zeppa.  Liquid-Based Cytology: A 25-Year Bridge between the Pap Smear and Molecular Cytopathology , 2014, Acta Cytologica.

[17]  G. Troncone,et al.  Epidermal Growth Factor Receptor Test Performed on Liquid-Based Cytology Lung Samples: Experience of an Academic Referral Center , 2014, Acta Cytologica.

[18]  G. Troncone,et al.  EGFR analysis: Current evidence and future directions , 2014, Diagnostic cytopathology.

[19]  J. Reynolds,et al.  EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC). , 2014, Lung cancer.

[20]  P. Vielh,et al.  Is Liquid-Based Cytology the Magic Bullet for Performing Molecular Techniques? , 2014, Acta Cytologica.

[21]  A. Chella,et al.  Anaplastic lymphoma kinase gene rearrangements in cytological samples of non–small cell lung cancer: Comparison with histological assessment , 2014, Cancer cytopathology.

[22]  J. Reynolds,et al.  ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  J. Heymann,et al.  The state of cell block variation and satisfaction in the era of molecular diagnostics and personalized medicine , 2014, CytoJournal.

[24]  E. Duncavage,et al.  Targeted next‐generation sequencing using fine‐needle aspirates from adenocarcinomas of the lung , 2014, Cancer cytopathology.

[25]  Rashmi Kanagal-Shamanna,et al.  Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics , 2014, Modern Pathology.

[26]  S. Thongprasert,et al.  A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER) , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[27]  S. Ren,et al.  High feasibility of liquid-based cytological samples for detection of EGFR mutations in Chinese patients with NSCLC. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[28]  Dario de Biase,et al.  Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy) , 2013, PloS one.

[29]  E. Mclean,et al.  ALK rearrangements in EBUS‐derived transbronchial needle aspiration cytology in lung cancer , 2013, Cytopathology : official journal of the British Society for Clinical Cytology.

[30]  P. Stephens,et al.  Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasms , 2013, Cancer cytopathology.

[31]  M. Fassan,et al.  Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel , 2013, PloS one.

[32]  L. Pantanowitz,et al.  Ancillary techniques on direct‐smear aspirate slides: A significant evolution for cytopathology techniques , 2013, Cancer cytopathology.

[33]  G. Troncone,et al.  EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non–small cell lung carcinoma patients , 2013, Cancer cytopathology.

[34]  B. Betz,et al.  The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma , 2013, Cancer cytopathology.

[35]  L. Bubendorf,et al.  Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  G. da Cunha Santos.  Standardizing preanalytical variables for molecular cytopathology , 2013, Cancer cytopathology.

[37]  A. Dejmek,et al.  Preparation of DNA from cytological material , 2013, Cancer cytopathology.

[38]  E. Imyanitov,et al.  Detection of EGFR mutations and EML4‐ALK rearrangements in lung adenocarcinomas using archived cytological slides , 2013, Cancer cytopathology.

[39]  Robert Brian Jenkins,et al.  Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[40]  T. Mitsudomi,et al.  Personalized therapy on the horizon for squamous cell carcinoma of the lung. , 2013, Lung cancer.

[41]  G. Giaccone,et al.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. , 2013, Archives of pathology & laboratory medicine.

[42]  M. Zorzetto,et al.  EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells , 2013, Journal of Cancer Research and Clinical Oncology.

[43]  M. Roh,et al.  Reply to Ancillary techniques on direct‐smear aspirate slides , 2013, Cancer cytopathology.

[44]  M. Roh,et al.  Ancillary techniques on direct‐smear aspirate slides , 2013, Cancer cytopathology.

[45]  A. Paradiso,et al.  Molecular Profiling of Thin-Prep FNA Samples in Assisting Clinical Management of Non-Small-Cell Lung Cancer , 2013, Molecular Biotechnology.

[46]  A. Marchetti,et al.  Effective Assessment of egfr Mutation Status in Bronchoalveolar Lavage and Pleural Fluids by Next-Generation Sequencing , 2012, Clinical Cancer Research.

[47]  D. Arenberg,et al.  The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma , 2012, Diagnostic cytopathology.

[48]  S. Monaco.  Cytopathology of lung cancer: moving from morphology to molecular , 2012 .

[49]  M. Zakowski,et al.  Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. , 2012, Lung cancer.

[50]  D. Amadori,et al.  Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients. , 2012, International journal of oncology.

[51]  M. Nishimura,et al.  The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer , 2012, Oncology.

[52]  G. Troncone,et al.  EGFR mutations detection on liquid-based cytology: is microscopy still necessary? , 2012, Journal of Clinical Pathology.

[53]  W. Travis,et al.  Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[54]  B. Betz,et al.  The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. , 2011, American journal of clinical pathology.

[55]  G. Troncone,et al.  EGFR and KRAS mutations detection on lung cancer liquid-based cytology: a pilot study , 2011, Journal of Clinical Pathology.

[56]  E. Mclean,et al.  Screening for EGFR and KRAS Mutations in Endobronchial Ultrasound Derived Transbronchial Needle Aspirates in Non-Small Cell Lung Cancer Using COLD-PCR , 2011, PloS one.

[57]  J. Pérez-Gracia,et al.  Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. , 2011, The oncologist.

[58]  G. da Cunha Santos,et al.  EGFR gene status in cytological samples of nonsmall cell lung carcinoma , 2011, Cancer cytopathology.

[59]  Gregg Staerkel,et al.  EGFR and KRAS mutations in lung carcinoma , 2011, Cancer cytopathology.

[60]  W. Travis,et al.  Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[61]  M. Tsao,et al.  Detection of EGFR and KRAS mutations in fine‐needle aspirates stored on Whatman FTA cards , 2010, Cancer cytopathology.

[62]  M. Ladanyi,et al.  Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. , 2010, The Journal of molecular diagnostics : JMD.

[63]  A. Iafrate,et al.  A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry , 2010, Clinical Cancer Research.

[64]  V. Macaulay,et al.  EGFR Mutations and Lung Cancer , 2005, PLoS Medicine.

[65]  F. Pontén,et al.  A high frequency of sequence alterations is due to formalin fixation of archival specimens. , 1999, The American journal of pathology.